{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:05:49Z","timestamp":1793217949888,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.thromres.2020.11.036","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T02:33:47Z","timestamp":1606876427000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"198","author":[{"given":"Mohammad","family":"Alhousani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Ullah","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abu-Hashyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah John","family":"Poznanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Al-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Frances","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alsharedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisher","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.thromres.2020.11.036_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4 Suppl","key":"10.1016\/j.thromres.2020.11.036_bb0010","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: a public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am. J. Prev. Med."},{"issue":"7","key":"10.1016\/j.thromres.2020.11.036_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.thromres.2020.11.036_bb0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/CIRCOUTCOMES.110.958397","article-title":"Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism","volume":"4","author":"Ng","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"1","key":"10.1016\/j.thromres.2020.11.036_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.thromres.2020.11.036_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11239-016-1437-1","article-title":"Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics","volume":"43","author":"Dobrowolski","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"5","key":"10.1016\/j.thromres.2020.11.036_bb0035","first-page":"874","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.thromres.2020.11.036_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M19-0087","article-title":"Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis","volume":"171","author":"Ha","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2020.11.036_bb0045","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2352-3026(18)30191-1","article-title":"Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis","volume":"6","author":"Dawwas","year":"2019","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2020.11.036_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.thromres.2020.11.036_bb0055","unstructured":"Cockcroft Dw Fau - Gault MH, Gault MH. Prediction of Creatinine Clearance From Serum Creatinine. (1660\u20138151 (Print))."},{"key":"10.1016\/j.thromres.2020.11.036_bb0060","author":"US Food and Drug Administration"},{"key":"10.1016\/j.thromres.2020.11.036_bb0065","series-title":"May 7, 2019: Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting Announcement - 05\/07\/2019 - 05\/07\/2019. FDA","year":"2019"},{"issue":"7414","key":"10.1016\/j.thromres.2020.11.036_bb0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj."},{"issue":"15","key":"10.1016\/j.thromres.2020.11.036_bb0075","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.thromres.2020.11.036_bb0080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral Apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2020.11.036_bb0085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2020.11.036_bb0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2020.11.036_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-9560-12-25","article-title":"Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment","volume":"12","author":"Bauersachs","year":"2014","journal-title":"Thromb. J."},{"issue":"11","key":"10.1016\/j.thromres.2020.11.036_bb0100","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"05","key":"10.1016\/j.thromres.2020.11.036_bb0105","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism\u2014analysis of the CATCH study","volume":"118","author":"Lee","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2020.11.036_bb0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2020.11.036_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11239-019-01833-w","article-title":"Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study","volume":"47","author":"Woodruff","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"issue":"8","key":"10.1016\/j.thromres.2020.11.036_bb0120","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2020.11.036_bb0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1740774515586176","article-title":"Measures of follow-up in time-to-event studies: why provide them and what should they be?","volume":"12","author":"Betensky","year":"2015","journal-title":"Clin Trials."},{"issue":"1","key":"10.1016\/j.thromres.2020.11.036_bb0130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.thromres.2020.11.036_bb0135","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2020.11.036_bb0140","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2020.11.036_bb0145","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/heartjnl-2016-309266","article-title":"Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease","volume":"103","author":"Yang","year":"2017","journal-title":"Heart."},{"issue":"5","key":"10.1016\/j.thromres.2020.11.036_bb0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mayocp.2013.03.006","article-title":"The new oral anticoagulants in clinical practice","volume":"88","author":"Gonsalves","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.thromres.2020.11.036_bb0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2013040361","article-title":"Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD","volume":"25","author":"Harel","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"24","key":"10.1016\/j.thromres.2020.11.036_bb0160","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2020.11.036_bb0165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.thromres.2020.11.036_bb2005","author":"Catella","year":"2020","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.11.036_bb2010","author":"Goldhaber","year":"2017","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.11.036_bb2015","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2020.11.036_bb2020","author":"Woodruff","year":"2019","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.thromres.2020.11.036_bb2025","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.thromres.2020.11.036_bb2030","author":"Hughes","year":"2014","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.thromres.2020.11.036_bb2035","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.thromres.2020.11.036_bb2040","author":"Brodsky","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.thromres.2020.11.036_bb2045","author":"B\u00f6hm","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.thromres.2020.11.036_bb2050","author":"Fordyce","year":"2016","journal-title":"Circulation."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820306447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820306447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:43:56Z","timestamp":1758735836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820306447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":43,"alternative-id":["S0049384820306447"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.11.036","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.11.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}